Aegerion Pharmaceuticals IncFind Ratings Reports
AEGERION PHARMACEUTICALS INC's gross profit margin for the second quarter of its fiscal year 2016 has significantly decreased when compared to the same period a year ago. Sales and net income fell significantly, underperforming compared to the average company in its industry. AEGERION PHARMACEUTICALS INC has weak liquidity. Currently, the Quick Ratio is 0.66 which shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
At the same time, stockholders' equity ("net worth") has significantly decreased by 92.57% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY16||Q2 FY15|
|Net Sales ($mil)||44.53||64.2|
|Net Income ($mil)||-46.81||-11.15|
|Balance Sheet||Q2 FY16||Q2 FY15|
|Cash & Equiv. ($mil)||72.21||82.56|
|Total Assets ($mil)||375.88||449.65|
|Total Debt ($mil)||268.53||249.08|
|Profitability||Q2 FY16||Q2 FY15|
|Gross Profit Margin||62.18||86.68|
|Return on Assets||-42.22||-9.1|
|Return on Equity||-1427.01||-27.35|
|Debt||Q2 FY16||Q2 FY15|
|Share Data||Q2 FY16||Q2 FY15|
|Shares outstanding (mil)||29.5||28.6|
|Div / share||0.0||0.0|
|Book value / share||0.38||5.24|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||470530.0||901686.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 5.86 indicates a significant premium versus the S&P 500 average of 2.73 and a significant discount versus the industry average of 9.73. The price-to-sales ratio is well below both the S&P 500 average and the industry average, indicating a discount. After reviewing these and other key valuation criteria, AEGERION PHARMACEUTICALS INC proves to trade at a discount to investment alternatives within the industry.
|AEGR NM||Peers 41.14||AEGR NM||Peers 20.33|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
AEGR's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
AEGR's P/CF is negative making the measure meaningless.
|AEGR NM||Peers 33.21||AEGR NA||Peers 0.45|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
AEGR's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|AEGR 5.86||Peers 9.73||AEGR -278.32||Peers -0.18|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
AEGR is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, AEGR is expected to significantly trail its peers on the basis of its earnings growth rate.
|AEGR 0.33||Peers 573.55||AEGR -10.24||Peers 51.13|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
AEGR is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
AEGR significantly trails its peers on the basis of sales growth